Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in PNH
NCT02605993Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2016
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Started Jan 2016; status: completed.
02
Drugs
ravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT02605993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02605993.